<DOC>
	<DOCNO>NCT00605826</DOCNO>
	<brief_summary>The purpose study determine effectiveness safety NASHA/Dx use injectable bulking agent treatment fecal incontinence . The study include 6-month blind sham-controlled phase , follow open-label phase .</brief_summary>
	<brief_title>A Randomized , Blinded , Multicenter Study Evaluate NASHA/Dx Treatment Fecal Incontinence</brief_title>
	<detailed_description>Subjects sham control group option receive open-label treatment NASHA/Dx blind phase .</detailed_description>
	<mesh_term>Fecal Incontinence</mesh_term>
	<criteria>1875 year age , male female Screening fecal incontinence severity score ( CCFIS ) Fecal incontinence episodes 14day period Failed conservative treatment fecal incontinence Complete external sphincter disruption Significant anorectal disease Anorectal surgery within last 12 month prior study Active Inflammatory Bowel Disease ( IBD ) Immunodeficiency receive immunosuppressive therapy Malignancies remission le 2 year prior study Bleeding disorder receive anticoagulant therapy Chemotherapy within last 12 month prior study Prior Pelvic radiotherapy Women pregnant breastfeeding , woman childbearing potential practicing adequate contraception plan stop contraception within first year study Women within one year post partum Participation clinical study within 3 month prior study Hypersensitivity hyaluronic acid containing product Other severe condition way unsuitable participate accord investigator judgement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>